German biotechnology company Topas Therapeutics has partnered with Boehringer Ingelheim to focus on antigen-specific tolerance induction to tackle anti-drug antibodies (ADA).

The multi-year collaboration and option agreement will involve the development of next-generation vector-based vector therapeutics using Topas’s tolerising nanoparticle technology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Virus-based delivery vectors are currently used to fight cancer. However, such therapeutics can result in an unwanted immune reaction, preventing repeated use.

Topas’s technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. Peptide-loaded nanoparticles mimic bloodborne antigens, selectively target liver sinusoidal endothelial cells, and generate antigen-specific regulatory T cells that suppress unwanted immune reactions.

“The high level of interest we have seen in our technology, including this key collaboration with Boehringer Ingelheim, supports the growing recognition of the importance of tolerance induction in drug development.”

Topas Therapeutics CEO Timm Jessen said: “This collaboration supports the value and broad applicability of our tolerance induction approach, now comprising the increasingly significant field of novel therapeutics and their precise delivery.

“The high level of interest we have seen in our technology, including this key collaboration with Boehringer Ingelheim, supports the growing recognition of the importance of tolerance induction in drug development, and we believe will fuel Topas’ future commercial potential.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topas will design, apply and produce the tolerising particles and Boehringer will offer its knowledge on antigen and pharmacology to aid the development of tolerance-generating adjuvant candidates.

Boehringer has the option to license various pre-clinical development candidates from the agreement, and will be responsible for their development and commercialisation.

Financial details of the partnership have not been disclosed.